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Abstract
Background/Aim: Incomplete or limited long-chain fatty acid (LCFA) combustion in skeletal muscle has been associated
with insulin resistance. Signals that are responsive to shifts in LCFA b-oxidation rate or degree of intramitochondrial
catabolism are hypothesized to regulate second messenger systems downstream of the insulin receptor. Recent evidence
supports a causal link between mitochondrial LCFA combustion in skeletal muscle and insulin resistance. We have used
unbiased metabolite profiling of mouse muscle mitochondria with the aim of identifying candidate metabolites within or
effluxed from mitochondria and that are shifted with LCFA combustion rate.
Methodology/Principal Findings: Large-scale unbiased metabolomics analysis was performed using GC/TOF-MS on buffer
and mitochondrial matrix fractions obtained prior to and after 20 min of palmitate catabolism (n=7 mice/condition). Three
palmitate concentrations (2, 9 and 19 mM; corresponding to low, intermediate and high oxidation rates) and 9 mM palmitate
plus tricarboxylic acid (TCA) cycle and electron transport chain inhibitors were each tested and compared to zero palmitate
control incubations. Paired comparisons of the 0 and 20 min samples were made by Student’s t-test. False discovery rate
were estimated and Type I error rates assigned. Major metabolite groups were organic acids, amines and amino acids, free
fatty acids and sugar phosphates. Palmitate oxidation was associated with unique profiles of metabolites, a subset of which
correlated to palmitate oxidation rate. In particular, palmitate oxidation rate was associated with distinct changes in the
levels of TCA cycle intermediates within and effluxed from mitochondria.
Conclusions/Significance: This proof-of-principle study establishes that large-scale metabolomics methods can be applied
to organelle-level models to discover metabolite patterns reflective of LCFA combustion, which may lead to identification of
molecules linking muscle fat metabolism and insulin signaling. Our results suggest that future studies should focus on the
fate of effluxed TCA cycle intermediates and on mechanisms ensuring their replenishment during LCFA metabolism in
skeletal muscle.
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Introduction
Long-chain fatty acids (LCFA) are a crucial energy source in
mammalian peripheral tissues, including skeletal muscle. During
fasting physiological suppression of glucose uptake and oxidation
in muscle is an important feature of the shift to greater FA
oxidation (FAO) rate [1], enabling glucose to be spared for cells
that have an obligatory requirement for that substrate. Suppressed
glucose uptake and oxidation can, however, develop despite
plentiful glucose supply, leading eventually to the development of
type 2 diabetes (T2DM) [2]. Insulin resistance in skeletal muscle
has important consequences in this regard because this tissue
contributes substantially to whole body insulin-mediated glucose
disposal.
It is well established that FAs and other lipid species can
modulate signaling pathways in skeletal muscle, including insulin
signaling [2,3]. With the exceptions of the diacylglycerides and
ceramides, the mechanisms through which lipid species can impair
insulin signaling remain poorly understood [4,5,6,7,8]. In
particular, the relationship between mitochondrial FA uptake/
oxidation and insulin sensitivity in muscle is controversial.
Individuals with T2DM have lower skeletal muscle FAO rates in
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mitochondrial content [11], decreased expression of oxidative
phosphorylation genes [12,13], and decreased maximal NADH-
linked phosphorylating respiration in isolated mitochondria
[14,15]. First degree relatives of T2DM patients also exhibited
reduced muscle mitochondrial content [16] and impaired
switching to FAO and mitochondrial adaptation to a high-fat diet
[17]. In rats, overexpression of carnitine palmitoyltransferase 1, a
key controlling enzyme in FAO, at physiologic levels improved
insulin sensitivity [18]. These findings have suggested that
impaired FAO (and mitochondrial function) promotes insulin
resistance. Yet other studies using pharmacological, dietary or
genetic interventions have linked insulin resistance in muscle to
increased FAO rates [19,20,21,22,23]. Moreover, improved
insulin sensitivity was correlated with lower FAO rate despite
higher intramuscular long-chain acyl-CoA species [22]. Thus a
shift from lipid oxidation to storage does not necessarily promote
insulin resistance. It has been proposed that insulin resistance is
associated with excessive flux through b-oxidation relative to
tricarboxylic acid cycle (TCA) capacity [22,24], a phenomenon
termed mitochondrial FA overload [22].
Collectively, the above raises the possibility that metabolites
associated with mitochondrial FA utilization are important in
determining insulin action in muscle. However, beyond the acyl-
carnitine species [22,25,26,27], the metabolites associated with
skeletal muscle mitochondrial FAO are poorly explored. Here, we
have utilized the novel technology of global metabolomics in
combination with a unique experimental design to identify
metabolite signatures of LCFA combustion in skeletal muscle
mitochondria oxidizing palmitate at different rates. This experi-
mental approach allowed the intra- and extra-mitochondrial
localization of metabolites, along with determinations of altered
pathway flux. Ultimately, the identification of muscle mitochon-
drial metabolites may reveal candidate molecules and/or path-
ways linking mitochondrial FA handling and lipid-mediated
modulation of insulin signaling.
Methods
Animals and Reagents
Female C57Bl/6J mice (n=7) were obtained from Jackson
Laboratories at 4 months of age, housed in our facility at 23uC
(12:12 hr light cycle, lights on 0700), with free access to chow
(4.5% fat/weight; Charles River-5075), for at least 1 week before
being studied. Animals were cared for in accordance with the
principles and guidelines of the Canadian Council on Animal Care
and the Institute of Laboratory Animal Resources (National
Research Council). This study was approved by the Animal Care
Committee of the University of Ottawa. Unless otherwise stated,
reagents were from Sigma (Oakville, ON, Canada).
Isolation of Mitochondria from Skeletal Muscle
Skeletal muscle mitochondria were isolated essentially according
to Chappell and Perry [28]. All media were ice-cold, and
procedures done on ice or at 4uC. Briefly, pectoral, forelimb and
hindlimb muscles were rapidly dissected and placed in basic
medium [BM (mM): KCl (140), HEPES (20), MgCl2 (5), EGTA
(2); pH 7.0]. Together, these muscle groups comprise a mixed
population of mainly type II oxidative and glycolytic fibers. Muscle
was cleaned of connective tissue and fat, minced and placed in 15
vol of homogenizing medium (HM: BM with 1 mM ATP and 1%
BSA (w/v)) containing one unit of protease (Subtilisin A) per g
muscle wet weight. Tissue was homogenized using a glass/Teflon
Potter-Elvehjem tissue grinder (240 rpm) and fractionated by
centrifugation at 800 g (10 min), and the supernatant collected
and spun at 12000 g (9 min). The pellet was resuspended in 20 ml
BM and incubated on ice for 5 min (myofibrillar repolymeriza-
tion). Samples were spun at 800 g (8 min) to pellet actin-myosin
polymers. The supernatant was then spun at 12000 g (9 min). The
final pellet was resuspended in 220 ml of BM. This isolation
procedure yields mitochondria with high respiratory control ratios
(state 3/state 4; ,8–10 when supplied with 10 mM pyruvate/
5 mM malate), and which are capable of activating palmitate [29],
a process dependent on the integrity of enzymes on the
mitochondrial outer membrane. Protein concentration was
determined by a modified Lowry method with BSA as standard.
Incubation Conditions
Each of the 7 mitochondrial preparations derived from
independent mice was tested in all treatment conditions.
Mitochondria (0.6 mg/ml) were supplied with three concentra-
tions of palmitate corresponding to low (2 mM), medium (9 mM)
and high (19 mM) rates of b-oxidation [29]. Three ml aliquots of
incubation medium [IM, (mM): KCl (120), HEPES (5), KH2PO4
(5), MgCl2 (5) and EGTA (1); pH 7.4] were supplemented with
(mM) ATP (1), malate (0.05), coenzyme A (0.025), and carnitine
(0.5) and added to 20-ml glass reaction vials. Solutions of low,
medium and high palmitate concentrations were added to vials in
a 6:1 FA:BSA complex. Palmitate was solubilized in ethanol; the
final concentration of ethanol in the reaction mixture was 0.5%.
Two additional incubations were performed as controls. The first
control condition (0 mM palmitate) evaluated the metabolic profile
of mitochondria oxidizing only malate, and included ATP,
carnitine and CoA and ethanol (0.5%). The second control
condition (9 mM palmitate + inhibitors) assessed effects of FA in
the absence of complete oxidative catabolism, and consisted of
malate, 9 mM palmitate, ATP, carnitine and CoA, and supple-
mented with the TCA cycle inhibitor malonate (10 mM) and the
electron transport chain complex I inhibitor rotenone (5 mM) [30].
Experimental Design
Figure 1 summarizes the experimental design. Each mitochon-
drial preparation (n=7) was tested in each of the five conditions
described above: 0, 2, 9, and 19 mM palmitate, and 9 mM
palmitate + inhibitors. Vials were pre-warmed for 5 min at 37uC,
and mitochondria were added to initiate the reaction. Immediately
upon addition of mitochondria, half of each reaction mixture was
transferred to tubes submerged in an ice slurry (‘time 0 min’
fraction); the time 0 fraction remained in the ice slurry for ,2
minutes prior to centrifugation (see below). The second half was
incubated for 20 min at 37uC, and the reaction stopped on ice as
for the time 0 min fraction (‘time 20 min’ fraction). This timed
sampling enabled later estimation of flux. Our choice of the 20-
min time point is based on pilot experiments showing that the rate
of CO2 production was similar with a 20 or 60 min incubation.
At each time point (time 0 and 20 min), aliquots were separated
into mitochondrial and buffer compartments by centrifugation
(12000 g, 3 min, 4uC). A 1300-ml aliquot of the incubation
medium (‘buffer’ fraction) was transferred to an empty tube, flash-
frozen in liquid N2, then stored at 280uC; removal of only a
fraction of the buffer ensured that the mitochondrial pellet was not
disrupted. The remaining incubation medium was carefully
removed and discarded, with care taken to remove as much of
the medium as possible with minimal disruption of the pellet.
Pellets were resuspended in 100 ml of IM without supplementa-
tion. A series of six freeze-thaw cycles (liquid N2 and 37uC) was
used to disrupt mitochondrial membranes. Membranes were
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collected (‘matrix’ fraction).
Metabolite Identification
Matrix and buffer samples were supplemented with 13 internal
standards for retention index correction (C8-C30 fatty acid methyl
esters) as previously reported [31]. Samples were subsequently
dried down and derivatized with 2 ml of a solution of 20 mg/ml of
98% pure methoxyamine hydrochloride in pyridine at 30uC for
90 min to protect aldehyde and ketone groups. 8 ml of MSTFA
with 1% TMCS (Pierce, Rockford IL) was added for trimethylsi-
lylation of acidic protons at 37uC for 30 min. 1 ml of this mixture
was injected by a Gerstel automatic liner exchange system and
CIS cold injection system (Gerstel, Muehlheim, Germany). For
every 10 samples, a fresh multibaffled liner was inserted (Gerstel
#011711-010-00) using the Maestro1 Gerstel software (version
1.1.4.18). Before and after each injection, the 10 ml injection
syringe was washed three times with 10 ml ethyl acetate. The
injector was operated in splitless mode, opening the split vent after
25 s. Chromatography was performed on an Agilent 6890 gas
chromatograph (Santa Clara CA), under control of the Leco
ChromaTOF software (version 2.32) (St. Joseph MI), using a 30 m
long, 0.25 mm i.d. Rtx-5Sil MS column with 0.25 mm 95%
dimethyl 5% diphenyl polysiloxane film and an additional 10 m
integrated guard column (Restek, Bellefonte PA). Helium carrier
gas was set at a constant flow of 1 ml/min with an oven
temperature ramp starting at 50uC for 1 min and then ramped at
20uC/min to 330uC at which point it was held constant for 5 min.
Mass spectra were acquired using a Leco Pegasus IV time of flight
mass spectrometer with a transfer line temperature of 280uC and
electron impact ionization at 70 V under a mass resolving power
R=600 from m/z 85–500 at 10 spectra s
21 and 1850 V detector
voltage. The instrument performed autotuning for mass calibra-
tion using FC43 (perfluorotributylamine) and a 4-point calibration
using a quality control mixture of 30 known metabolites before
starting analysis sequences. ChromaTOF (version 2.32) was used
for data preprocessing without smoothing, 3 s peak width, baseline
subtraction just above the noise level, automatic mass spectral
deconvolution and peak detection at signal/noise levels of 10:1
throughout the chromatogram. Result *.txt files were exported to a
data server with absolute spectra intensities and further processed
by the BinBase algorithm [32] for removing inconsistent and noisy
spectra. Metabolites were identified in BinBase and its underlying
Fiehn mass spectral library using retention index windows of 6
2,000 units (around 6 2 s retention time deviation) and mass
spectral similarity thresholds that varied upon signal/noise ratios
and mass spectral purity values as given in supplemental data of
Fiehn et al. [31].
Data Analysis
Metabolite values were log transformed, and subsequent
analysis was performed on these values. Data are presented as
log-transformed; log transformation of metabolite data can
generally be taken as normally distributed [33], justifying the use
of parametric analysis. Each incubation condition was tested in
each mitochondrial preparation, therefore paired analyses were
performed. Thus, for each metabolite, comparison between the 0
and 20 min values for each metabolite was made by paired
Student’s t-test. To account for multiple comparisons, each false
discovery rate (FDR) was estimated by the product of the
significance level (Type I error rate) and the number of null
hypotheses tested divided by the number of null hypotheses
Figure 1. Summary of experimental design used to determine metabolite shifts in murine muscle mitochondrial preparations
under different rates of LCFA b-oxidation. Conditions: incubations with/without palmitate, in the absence or presence of inhibitors (inh; 10 mM
malonate, 5 mM rotenone). Times: subsamples of mitochondrial suspension removed at 0 and 20 min for subsequent metabolomics determinations.
Fractions: mitochondrial suspensions were separated into matrix (M) and buffer (B). GC/TOF-MS: gas chromatography, time-of-flight mass
spectroscopy.
doi:10.1371/journal.pone.0009834.g001
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was performed using Grubbs’ test. A single outlier was removed in
each of only 11 data sets; this is flagged for the affected
comparisons. Unless otherwise indicated, values are presented as
the mean 6 SEM.
Results
Optimization of Flux Conditions
Mitochondria were supplied with three concentrations of
palmitate corresponding to low (2 mM), medium (9 mM) and high
(19 mM) rates of FAO, as determined previously using mitochon-
dria isolated and incubated under identical conditions as in the
current study, but tracking 1-[
14C]-palmitate [29]. Over this range
of palmitate concentration, flux of C16:0 carboxyl carbon to CO2
(i.e. complete oxidation) leveled off with increasing palmitate
concentration whereas incomplete oxidation, measured as the
14C-
label recovered in the acid soluble product of a lipid extraction,
increased linearly; thus there was a disproportionate increase in
incomplete relative to complete FAO (Figure S1). These
observations suggested that metabolite profiles of mitochondria
oxidizing palmitate at high versus low rates may differ substantially,
providing insight into how different LCFA oxidation rates impact
mitochondrial function and signaling from mitochondria. We
therefore determined metabolite profiles of mitochondria oxidizing
palmitate at low, medium and high rates. Two control conditions
were also assessed. To determine metabolite shifts under basal
conditions, the first control treatment contained all incubation
constituents except FA. The second control incubation assessed
the specificity of metabolite shifts observed with alterations in FAO
via inclusion of FAO inhibitors along with 9 mM palmitate.
To assess the bioenergetic status of mitochondria oxidizing
palmitate, O2 consumption was measured under the incubation
conditions used to generate samples for metabolomics analyses. As
presented in Table S1 (and explained in the accompanying text),
palmitate is oxidized under phosphorylating conditions, at a rate
between state 3 and state 4 but closer to state 3.
Metabolite profiling of the mitochondrial matrix and buffer
fractions enabled metabolite shifts between compartments to be
determined. In the matrix fraction, a decrease in metabolite
concentration indicates that mitochondrial catabolism of the
metabolite was increased and/or that the metabolite was effluxed
into the buffer fraction; insight into one or the other of these
interpretations can be gained by comparing changes in matrix and
buffer concentrations of a particular metabolite. Regarding an
increase in the concentration of a matrix metabolite, a distinction
cannot be made between an increase in a metabolite due to its net
synthesis versus one caused by a decrease in its degradation. A
further possible interpretation is an accumulation of a metabolite
due to its release from membrane-associated sites as could occur if
related enzymes exist as an organized, membrane-bound complex.
In the buffer fraction, an increase in the concentration of a
metabolite indicates efflux from the mitochondrial fraction,
whereas a reduction in concentration indicates mitochondrial
uptake.
Global Characteristics of the Metabolomics Data Set
The global characteristics of the metabolomics data set are
summarized in Tables 1 and 2, and Figures 2 and 3. Importantly,
only high-quality metabolic signals were reported after applying
the multi-tiered filtering algorithm implemented in the BinBase
database [31]. Approximately half of all detected signals per
chromatogram are not reported in the final data set due to these
Table 1. Global characteristics of metabolomics dataset.
Number of Observations
Total number of detected metabolites 197
Number of unambiguously identified
metabolites
51
Chemical Classes
Fatty acid species 15
Organic acids 10
Amino acids 8
Carbohydrates 5
Phosphates 4
Alcohols 3
Nucleotides 2
Amines 2
Steroids 1
Inorganic ions 1
doi:10.1371/journal.pone.0009834.t001
Table 2. Estimated false discovery rates (FDR), P value threshold (paired t-test), and corresponding number of metabolites (#) that
changed over the 20-min incubation in each fraction (matrix, buffer).
Condition FDR, % P value # FDR, % P value # FDR, % P value # FDR, % P value #
Matrix 0 mM 31 0.05 32 23 0.035 30 19 0.02 20 19 0.005 5
2 mM 21 0.05 48 16 0.035 42 14 0.02 28 11 0.005 9
9 mM 28 0.05 35 20 0.035 30 18 0.02 18 14 0.005 7
19 mM 21 0.05 46 17 0.035 41 14 0.02 33 9 0.005 11
9 mM+inh 21 0.05 50 17 0.035 40 13 0.02 31 7 0.005 15
Buffer 0 mM 25 0.05 36 23 0.035 20 19 0.02 21 14 0.005 7
2 mM 32 0.05 31 28 0.035 23 33 0.02 12 16 0.005 6
9 mM 75 0.05 13 48 0.035 13 48 0.02 8 33 0.005 3
19 mM 70 0.05 14 76 0.035 7 46 0.02 7 20 0.005 3
9 mM+inh 33 0.05 30 34 0.035 20 26 0.02 15 16 0.005 6
Condition: concentration of palmitate; inh: inhibitors added.
doi:10.1371/journal.pone.0009834.t002
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metabolite must be confirmed with high mass spectral similarity
and at the correct retention index in at least 80% of the samples in
at least one of the treatment classes of the experimental design
[31]. This leads to a very conservative assessment of the number of
identified metabolites that nevertheless spans various chemical
classes from medium and long-chain free fatty acids and steroids to
organic phosphates, polar and non-polar amino acids and
hydroxyl acids (Table 1). Raw and processed data sets can be
downloaded from SetupX, detailing the total of 197 analytes that
were reliably detected after BinBase processing and annotating the
51 metabolites that were unambiguously identified by PubChem
and KEGG database identifiers. All metabolites were further
characterized by the ion trace used for quantification, the
retention index, the BinBase identifier and the full mass spectrum
encoded as a string in the result tables (Table S2 and downloads
from SetupX [http://fiehnlab.ucdavis.edu:8080/m1/main_public.
jsp]).
False discovery rate (FDR) estimates, P value threshold and
numbers of metabolites for each FDR and P values are presented
in Table 2. Due to stringent quality control filters which
minimized the number of reported metabolites, and the use of a
conservative FDR estimator, a P value threshold of 0.05 was
selected for presentation and discussion of results despite the high
FDR estimates for some conditions.
Global representations of the data set are presented as a heat
map (Figure 2) as well as in Table S2. The heat map depicts only
identified metabolites that changed significantly in at least one
condition over the 20-min incubation. Intensity and color are
based on the degree of significance and direction of change,
respectively. Degree of significance was utilized to emphasize the
robust time-dependent changes in the data set. Some patterns,
Figure 2. Heat map showing the identified metabolites from murine muscle mitochondrial preparations that changed in
concentration over the course of the incubations. Metabolites are shown for which the concentration changed significantly during the 20-min
incubation for one or more of the treatment conditions (0, 2, 9, and 19 mM palmitate, and 9 mM palmitate plus FAO inhibitors).
doi:10.1371/journal.pone.0009834.g002
Figure 3. Numbers of metabolites that changed significantly in concentration (P,0.05, paired t-test) in buffer and matrix fractions
obtained from skeletal muscle mitochondria oxidizing LCFA at different rates.
doi:10.1371/journal.pone.0009834.g003
Metabolomics of LCFA Oxidation
PLoS ONE | www.plosone.org 5 March 2010 | Volume 5 | Issue 3 | e9834including patterns that are unique to FAO rate, are apparent from
the heat map. As a group, TCA cycle intermediates (TCAi) were
found to accumulate in both the matrix and the buffer; the pattern
of change depended on the condition (see below). Amino acids
tended to decrease in the matrix, and did so most robustly with
19 mM palmitate (see below). Fatty acids also tended to decrease in
the matrix at high FAO rate, but tended to accumulate in the
buffer fraction at the lowest FAO rate as well as in the presence of
inhibitors.
The numbers of metabolite shifts (0 vs. 20 min, P,0.05)
uniquely associated with FAO was a function of both experimental
condition and compartment (buffer or matrix) (Figure 3). Of
interest was the extent to which the number and direction of the
shifts differed among the three palmitate oxidation conditions. A
large number of metabolites accumulated with 2 mM palmitate in
both the matrix (27 metabolites) and the buffer (16 metabolites). In
contrast, oxidation of 19 mM palmitate was associated with a large
reduction in the number of matrix metabolites (32 metabolites)
whereas only one and two metabolites increased significantly in
the buffer and matrix respectively. The number of metabolites that
changed with 9 mM palmitate was intermediate between that with
high and low FAO rates. This overview of the data set indicates
that palmitate oxidation rate per se is associated with distinct
metabolite changes in both the matrix and buffer compartments.
Shifts in Selected Metabolites
As a validation of our methodology, we examined the changes
in palmitate and malate in the buffer fraction (Figure 4). As
expected, there was a significant reduction over the course of the
20 min reaction in the concentration of palmitate in the buffer
with medium (70610% decrease; P=0.02) and high (8565%
decrease; P,0.0001) palmitate supply, and no significant change
in palmitate concentration when inhibitors were present. Com-
plete and incomplete oxidation were measurable for the 2 mM
palmitate incubation (see Figure S1); however, a change in
palmitate could not be detected at this low palmitate supply. The
buffer was similarly depleted of malate, except when inhibitors
were present, as expected.
Some metabolites changed over time in all or in 4 of 5
conditions, in the same direction and by a similar magnitude,
indicating that these changes were not specific for any of the
treatment conditions. This occurred for 4 metabolites in the
matrix fraction (taurine, inositol, glucose, and unidentified analyte
219881) and illustrates the utility of the control conditions.
Among the metabolites identified by our unbiased approach,
the significant changes that were the most prominent in terms of
magnitude as well as showing a pattern related to FAO were the
TCAi, amino acids, and a ketone body species (3-hydroxybutanoic
acid).
TCA cycle intermediates. The detected TCAi were malate,
citrate, a-ketoglutarate (a-KG) and succinate. While significant
changes were observed in the matrix fraction, the most
pronounced changes were found in the buffer fraction. Citrate
accumulated in the buffer at the low (P=0.0007; ,130% increase)
and medium (P=0.03; ,30% increase) but not at the highest
palmitate concentration (Figure 5). Corresponding changes in
citrate were not detected in the matrix fraction, indicating citrate
production in the matrix during the 20 min incubation with
subsequent efflux. Export of citrate depended on substrate
oxidation since export was not detected with TCA cycle and
electron transport chain inhibition. In contrast, a large rise in
matrix citric acid was measured with oxidation of 19 mM
palmitate (P,0.001; ,800% increase), but interestingly there
was no significant export of this metabolite to the buffer.
Matrix levels of a-KG showed little change, with the exception
of a small increase with the lowest palmitate oxidation rate
(P,0.05). a-KG was found to accumulate in the buffer fraction
with increasing palmitate supply (P=0.02 and 0.003 for 9 mM and
19 mM palmitate, respectively) (Figure 5). An increase was also
detected in the zero palmitate control that was of a comparable
magnitude to that observed with 9 mM palmitate (,400%
increase), but less than that with 19 mM palmitate (,1400%
increase). These increases in buffer a-KG in the absence of a
reduction in the matrix suggest that net production of a-KG
occurred during the 20 min incubation. As for citrate, export of a-
KG was not detected in the presence of inhibitors. Taken with the
Figure 4. Change in the concentration of supplied substrates (palmitate, malate) in the buffer fraction obtained from murine
muscle mitochondria over the course of the incubations. All 5 conditions are shown (0, 2, 9 and 19 mM palmitate, and 9 mM palmitate plus
inhibitors). Values are the log of the change in concentration (peak height). Significance: paired t-test, 0 vs. 20 min, within treatment; * P,0.05; **,
P,0.02, *** P,0.005.
doi:10.1371/journal.pone.0009834.g004
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production rose with increasing palmitate b-oxidation, with robust
export of a-KG from the matrix space.
The absolute changes in matrix and buffer citrate and a-KG, as
well as the time 0 values, were estimated using standard curves and
the value of total extracted mitochondrial protein (,5m g
mitochondrial protein/ gram muscle wet weight) (see Methods
S1). The time 0 value for citrate of ,60 nmol/g muscle wet weight
was of the same magnitude as that reported from whole rat skeletal
muscle (80–180 nmol/g muscle wet weight; [37,38]). The reported
values were, however, from mainly type I whereas our muscle
contained primarily type II fibers which would be expected to
contain citrate levels due to lower mitochondrial content. The time
0 value for a-KG was ,33 nmol/g muscle wet weight, similar to
that in whole mouse heart [39]. Over the course of the 20-min
incubation with 19 mM palmitate, the calculated change in matrix
citrate was 1.4 nmol/min/g muscle wet weight. Incubation with
2 mM palmitate resulted in net accumulation of a-KG at
1.9 nmol/min/g muscle wet weight. During incubation with 2
and 9 mM palmitate, net citrate efflux occurred at 0.4 and
0.2 nmol/min/g muscle wet weight, respectively. Compared to
citrate, substantially higher net efflux rates were measured for a-
KG (2.6 and 8 nmol/min/g muscle wet weight during incubation
with 9 and 19 mM palmitate, respectively).
Matrix levels of succinate were not significantly changed in any of
the treatment conditions (Figure 5). In the buffer, only the succinate
in the zero palmitate control changed significantly, showing a
,200% increase (P,0.005). While there was a trend for such an
increase with increasing palmitate concentration, changes were not
significant. Changes in malate are confounded by its addition as a
substrate. However, it is noteworthy that matrix levels of malate
increased significantly in the presence of inhibitors (P,0.02;
,300% increase) as would be expected, but also increased with
19 mM palmitate (P=0.02; ,30% increase) (Table S2).
Amino acids. Seven amino acids were detected, including
both polar (serine, lysine) and non-polar (glycine, phenylalanine,
tyrosine, tryptophan, isoleucine) species (Figure 6). The most
pronounced and consistent change was a significant reduction in
the matrix levels of 5 amino acids (tyrosine, tryptophan,
phenylalanine, lysine, glycine) with oxidation of 19 mM
palmitate. Lysine was also reduced with 9 mM palmitate and in
the presence of inhibitors; therefore this change may not be related
to FAO per se. There was no corresponding accumulation in the
buffer of any of these five species, indicating net degradation in the
matrix fraction. Two species (tryptophan, phenylalanine)
accumulated in the buffer in either the inhibitor condition
(phenylalanine) or with 2 mM palmitate; a corresponding
reduction in the matrix was observed with phenylalanine only.
Figure 5. Changes in detected TCA cycle intermediates over time in buffer and matrix fractions obtained from muscle
mitochondrial preparations. All 5 conditions are shown (0, 2, 9 and 19 mM palmitate, and 9 mM palmitate plus inhibitors) for both fractions
(matrix and buffer). Values are the log of the change in concentration (peak height) over a 20-min incubation. Buffer and matrix fractions can be
compared within each metabolite. Significance: paired t-test, 0 vs. 20 min, within treatment; * P,0.05; **, P,0.02, *** P,0.005. {: indicates that an
outlier was removed from either the 0 or 20 min group for that metabolite in that fraction.
doi:10.1371/journal.pone.0009834.g005
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In the matrix fraction, a significant change in 3-OHBA was only
detected with oxidation of 19 mM palmitate (Figure 7). However, 3-
OHBA accumulated in the buffer in all palmitate conditions with
the exception of 9 mM palmitate for which there was a large degree
of variability in the sample set. For the 19 mM palmitate condition,
buffer accumulation exceeded matrix reduction (+76778622196 vs.
-11756316 arbitrary units). Thus, net synthesis of 3-OHBA is
suggested for the inhibitor+9 mM condition and concurrent with
FAO.
Unidentified metabolites. Mass spectra of unknown metab-
olites can be viewed and compared to other BinBase entries
through a web service [http://eros.fiehnlab.ucdavis.edu:8080/
binbase-compound/database/selectDatabase]. Many unknown
species were detected. However, only a small subset showed
significant changes specific to FAO; three such analytes are
presented in Figure 8. The overall pattern of change of these 3
metabolites was matrix disappearance with 19 mM palmitate and
buffer accumulation with 2 mM palmitate in the absence of a matrix
reduction. Other potential species of interest are: 215355, 217840,
222047, 222099.
Discussion
Long-chain FAs are a key carbon source in tissues that consume
ATP at high rates, such as cardiac muscle and skeletal muscle
during exercise or fasting. Cellular disposal of FA is associated with
reduced insulin-mediated glucose uptake [2], and a role for
mitochondrial FAO has been suggested [22]; however the
mechanistic basis for such a role is unknown. This question is of
particular interest given that b-oxidation flux may exceed TCA
Figure 6. Changes in detected amino acids over time in buffer and matrix fractions obtained from muscle mitochondrial
preparations. Significance: paired t-test, 0 vs. 20 min, within treatment; * P,0.05; **, P,0.02, *** P,0.005. See legend to Figure 5 for further details.
doi:10.1371/journal.pone.0009834.g006
Figure 7. Changes in 3-hydroxybutanoic acid over time in
buffer and matrix fractions obtained from muscle mitochon-
drial preparations. Significance: paired t-test, 0 vs. 20 min, within
treatment; * P,0.05; **, P,0.02, *** P,0.005. {: indicates that an outlier
was removed. See legend to Figure 5 for further details.
doi:10.1371/journal.pone.0009834.g007
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reflected in higher incomplete oxidation, and specifically in
increased serum and muscle levels of acylcarnitines [22].
Compartmentalization of these metabolites within muscle was
not determined, and other potential species of interest were not
identified. Here, we utilized unbiased metabolite profiling of
skeletal muscle mitochondria oxidizing LCFA at different rates to
provide insight into changes in mitochondrial function and
intermediary metabolism during FAO. Our approach demon-
strated overall that FAO and FAO rate are associated with unique
shifts in mitochondrial metabolites and with the efflux of
metabolites from mitochondria. Several pathways emerged as
being worthy of further study, namely the TCA cycle and ketone
body metabolism (Figure S2). Altogether our findings demonstrate
the power and applicability of the novel experimental design,
technology and analytical approaches utilized.
TCA Cycle Anaplerosis
Our observations indicate that titration of b-oxidation impacts
TCA cycle dynamics; that is, production and/or catabolism as
well as efflux of TCA cycle intermediates (TCAi). Supportive
evidence is summarized as follows. Changes in TCAi (citrate, a-
KG, succinate, malate) were detected in the matrix and buffer in
all conditions in which complete oxidation was possible (i.e., in the
absence of inhibitors), indicating that metabolite shifts depended
on TCA cycle and/or electron transport chain flux. In the case of
efflux into the buffer, passive exchange of existing pools of
intermediates with malate cannot explain these observations since
matrix levels of intermediates were never found to decrease. Efflux
is also unlikely to reflect non-specific leakage of metabolites from
mitochondria since only a small fraction of all detected metabolites
increased in the buffer in any of the conditions, and efflux of TCAi
was not even detected in the inhibitor condition. That the
Figure 8. Change over time in levels of selected unidentified metabolites in buffer and matrix fractions obtained from muscle
mitochondrial preparations. Significance: paired t-test, 0 vs. 20 min, within treatment; * P,0.05; **, P,0.02. See legend to Figure 5 for further
details.
doi:10.1371/journal.pone.0009834.g008
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change in the TCAi is striking (Figure 5). Buffer or matrix
accumulation of citrate and a-KG was apparent with FAO, and
the magnitude dependent on rate. However, a-KG also
accumulated in buffer with provisioning of malate alone (zero
palmitate control). While speculative, the significant increase in net
a-KG efflux with zero palmitate might be explained by net flux
toward succinate, since under these conditions there is minimal
fuel-derived acetyl-CoA to combine with oxaloacetate. In support
of this view, we observed a robust net efflux of succinate only in
the zero palmitate control condition. Finally, accumulation of
malate in the matrix was associated only with the highest FAO
rate, and a-KG accumulation in the buffer was also most apparent
in this condition. Thus, FAO rate appears to influence TCA cycle
dynamics. This interpretation concurs with some observations
made in the isolated working heart [40,41]; however important
differences between skeletal and cardiac muscle may exist, as
discussed below. Also, it is noteworthy that prior studies in skeletal
muscle only measured TCAi in whole muscle extracts
[37,38,42,43]; thus the present study is the first to compartmen-
talize TCAi in skeletal muscle and to directly link mitochondrial
TCAi efflux with FAO rate.
Each of the oxidizing conditions was associated with increased
matrix and/or buffer levels of intermediates without a reduction in
matrix levels. These observations could arise from one or a
combination of the following: increased synthesis of an interme-
diate; its slowed catabolism; its release from membrane-associated
sites. Anaplerosis of TCAi replenishes loss of carbon through
metabolites other than CO2. Anaplerotic generation of citrate and
a-KG in the present study concurs with previous reports in skeletal
and cardiac muscle [37,38,40,41,42,43]. Physiologically, the main
anaplerotic substrates are pyruvate, glutamate/glutamine, and
precursors of propionyl-CoA (some amino acids, odd-chain FAs,
and C5-ketone bodies) [44]. Here, exogenous malate was provided
as an anaplerotic substrate, and would be expected to contribute to
TCAi generation. In support, malate disappeared from the buffer
in all oxidizing conditions indicating its uptake by mitochondria,
and, except at the highest FAO rate, it did not accumulate in the
matrix indicating that it was catabolized. Possible additional
anaplerotic substrates in isolated mitochondria are stored pyruvate
and amino acids. It has however been suggested that isolated
muscle mitochondria contain only limited stores of pyruvate [45].
We detected amino acids in the matrix fraction and, interestingly,
levels tended to decrease with increased FAO, suggesting a link
between FAO rate and amino acid catabolism. It needs to be
recognized that of the seven detected amino acids, only two
(glycine and serine) are known to undergo initial breakdown in the
mitochondrial matrix. Initial catabolism of the other five is thought
to occur extra-mitochondrially, with subsequent import of
intermediates into the matrix. That we could detect the
disappearance of four of five of these amino acids without
accumulation in the buffer, and this disappearance was, with the
exception of lysine, confined to the highest FAO rate, implicate a
specific process that can be regulated by FAO. A possible scenario
is that these amino acids underwent catabolism, and thus that
related enzymes are intimately associated with skeletal muscle
mitochondria, and/or that amino acids in addition to glycine and
serine can be initially catabolized within the matrix.
Glycine was depleted in the matrix only at the highest FAO
rate. Glycine can be degraded to pyruvate via conversion to serine.
That there was no net accumulation of serine at the highest FAO
rate supports the possibility that serine was degraded to pyruvate.
Conversion of serine to pyruvate is believed to partially occur
extra-mitochondrially; again, it is possible that related enzymes are
either intimately associated with mitochondria or are present
within the matrix. Pyruvate can be degraded to a-KG via alanine
aminotransferase, or to citrate via carboxylation or decarboxyl-
ation. Notably, citrate and a-KG accumulated at the highest FAO
rate. As well, flux through each of the latter pathways has been
documented in muscle; flux through alanine aminotransferase
accounted for increased a-KG in skeletal muscle at the onset of
exercise [43], and, in the isolated working heart perfused with high
or low concentrations of oleate, both carboxylation and decar-
boxylation contributed to citrate production [41]. Little is known
about the role of pyruvate carboxylase activity in skeletal muscle
mitochondria except that the protein is expressed, albeit at lower
levels than in heart [46]. Increased oleate supply to the heart was
associated with reduced anaplerotic carboxylation and decarbox-
ylation of pyruvate [41]. Thus, at high FAO rate, pyruvate
conversion to TCAi may be minimal and flux through alanine
aminotransferase may become a more important anaplerotic
mechanism. Our overall approach, combined with targeted
metabolomics and the provision of isotopically-labelled anaplerotic
substrates, could be used in focused studies of anaplerosis during
FAO in skeletal muscle mitochondria.
Studies on the functional role of anaplerosis in muscle have
focused mainly on the heart and demonstrated that insufficient
anaplerosis leads to reduced contractile function (reviewed in [46]).
Yet in exercising skeletal muscle, interventions that limited
anaplerosis have not affected ATP production, even at VO2max
[43,47]. A role for anaplerosis in skeletal muscle is evident,
however, in the context of enhanced reliance on FAs or of
aberrant FAO. In patients with very long-chain acyl-dehydroge-
nase deficiency, the provision of anaplerotic triheptanoin relieved
muscle weakness [48]. In type 2 diabetics, plasma propionylcarni-
tine correlated inversely with HbA1c, suggesting reduced ana-
plerotic capacity with type 2 diabetes severity[24]. That matrix
levels of TCAi did not decrease in the present model indicates that
anaplerosis likely was not limiting and was well-matched to
removal of TCAi (‘cataplerosis’; e.g. [44]). However, if anaplerotic
capacity were diminished, ongoing efflux of intermediates would
lower TCA cycle capacity, reducing the oxidative disposal of
LCFA-CoA. Moreover, during FAO, a reduction in pyruvate as
an anaplerotic substrate may result from inhibition of mitochon-
drial uptake and lower anaplerotic utilization, as reported in hearts
supplied with FAs [41].
Efflux of TCA Cycle Intermediates
Citrate and a-KG were detected in the buffer fraction,
indicative of efflux from skeletal muscle mitochondria. Little
information exists on the efflux of TCAi from skeletal muscle
mitochondria, although studies in muscle extracts suggest that it
occurs [37,38]. In the isolated working heart supplied with
different concentrations of oleate, efflux of citrate, measured as
citrate release from whole heart, was observed, and the rate was
the same for high and low oleate concentrations [40,41]. We found
citrate efflux to be most robust at the lowest palmitate
concentration, measurable at the medium concentration, but not
significantly increased at the highest concentration. Thus, our
observation of a lack of significant mitochondrial citrate efflux at
the highest FAO rate differs from the situation in cardiac muscle.
The absence of malate as a counter-molecule for citrate exchange
cannot be an explanation since malate was supplied exogenously,
disappeared from the buffer fraction, and a fate other than
mitochondrial association seems unlikely. Competition by the
tricarboxylic acid and oxoglutarate carriers for malate is a
possibility. However, the Km values of the tricarboxylic acid
carrier for malate and citrate are lower than the Km values of the
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exchange of malate for citrate. Thus the difference between heart
and skeletal muscle in citrate efflux may depend on other factors
such as differential modulation of citrate or a-KG transport. In
heart supplied with isotopically labeled oleate, pyruvate and
lactate, and in skeletal muscle supplied with glucose and insulin,
effluxed citrate contributed to malonyl-CoA production
[37,38,40]. Both pyruvate and oleate contributed to the acetyl
moiety of malonyl-CoA in the heart [40]. Because our results
suggest that citrate export in skeletal muscle mitochondria depends
on FAO rate, and, at least at high FAO rate, to be differently
modulated relative to cardiac mitochondria, further investigation
into the association of malonyl-CoA with citrate and FAO rate in
skeletal muscle is warranted.
Ketone Body Production & TCA Cycle Activity
Hepatic ketone body production is a crucial source of acetyl-
CoA equivalents for other tissues including skeletal muscle, and
ketogenesis is a mechanism by which finite pools of matrix free
CoASH are maintained and reducing equivalents consumed to
support continued robust hepatic LCFA b-oxidation. Thus, much
of the 3-OHBA detected in the matrix fraction at time 0
presumably originated in the liver. However, as 3-OHBA
accumulated in the buffer in excess of its reduction in the matrix,
we can conclude that 3-OHBA was somehow produced in the
matrix. These changes in 3-OHBA occurred in the presence of
inhibitors, indicating that complete palmitate oxidation to CO2
was not required. Ketogenesis in muscle is, however, contentious.
Mitochondrial HMG CoA synthase, a key control point in
ketogenesis [50], has thus far only been reported in skeletal muscle
as a transcript [51]. As well, ketone body production in the heart
[52,53] has been explained by exchange between acetoacetate and
acetyl-CoA pools resulting from the reversibility of the ketolytic
reactions (‘pseudoketogenesis’) [53]. Thus, it is premature to
propose that our findings indicate true ketogenesis. Yet, they
warrant further investigation especially in light of the observed
export of 3-OHBA, as well as the association of 3-OHBA with
insulin resistance and reactive oxygen species formation [54,55].
Excess acetyl-CoA units, resulting from greater b-oxidation
relative to TCA cycle flux, would become available to generate 3-
OHBA or acetylcarnitine [22]. Potentially adding to this mismatch
is inactivation of aconitase or a-KG dehydrogenase by reactive
oxygen species [56,57], that are particularly associated with FAO
[58] (ELS, CE and MEH, unpublished observations). That we
could not detect peroxide emission from muscle mitochondria
under the same phosphorylating conditions as used here [29]
suggests that oxidative inactivation of aconitase or a-KG may not
be occurring in the present system. Nevertheless, it is notable that
under conditions of high FAO, we observed increased accumu-
lation of malate-citrate and a-KG, a pattern consistent with a
saturation or reduced activity of a-KG dehydrogenase activity
with increasing FAO. Such a hypothetical mechanism linking
FAO and TCA cycle metabolism warrants further examination.
Methodological considerations
The unique analytical approaches used in conjunction with
intact and highly functional mitochondria in the current study
have enabled specific analyses of complex mitochondrial processes.
An additional advantage of using an enriched mitochondrial
preparation instead of whole muscle is that it allows rapid
separation of mitochondrial matrix and extra-mitochondrial
fractions. It should be noted however that cellular components
extrinsic to mitochondria are present in the mitochondrial
preparation used here and in numerous published bioenergetic
studies. Yet, some extrinsic enzymes and organelles are linked to
mitochondria via protein-protein interactions. For example, the
endoplasmic reticulum is well known to be functionally and
physically linked to mitochondria in liver (e.g. [59]) and skeletal
muscle [60]. FA elongation occurring in the endoplasmic
reticulum may be the source of C.16 FA in the present study.
Hexokinase (I and II) is associated with the mitochondrial outer
membrane via binding to porin [61]. Binding of hexokinase II to
porin on skeletal muscle mitochondria has been reported [62], and
we have detected mitochondrial hexokinase activity (ELS, CE and
MEH, unpublished). Thus, flux through hexokinase likely
accounts for glucose disappearance in the matrix fraction; data
from control incubations indicate however that this is unrelated to
FA provisioning. Localization of lactic acid dehydrogenase to the
inner membrane of skeletal muscle mitochondria has also been
reported [63], and would account for lactic acid accumulation in
the matrix. It is likely that other enzymes not normally associated
with mitochondria will be identified in the future, such as glucose
6-phosphate dehydrogenase [64].
Peroxisomes also participate in b-oxidation, but do not chain-
shorten beyond 6 carbons. The acetyl-CoA and medium-chain
acyl-CoA species formed by peroxisomal b -oxidation are exported
to the cytosol where they are incorporated into biosynthetic
pathways or can enter mitochondria and be completely oxidized.
Thus it is possible that some of the detected fatty acids were
derived from peroxisomes. It is noteworthy, however, that, in the
absence of carnitine, O2 consumption is not detectable with
palmitate concentrations below 200 mM (ELS, CE, MEH,
unpublished observations); thus our results are likely to mainly
reflect mitochondrial processes. As well, since peroxisomes lack a
TCA cycle, the detected TCAi would have strictly originated in
mitochondria.
In summary, this ‘proof-of-principle’ mitochondrial metabolo-
mics study highlights that skeletal muscle FAO rate is associated
with distinct changes in metabolites within and exported from
mitochondria. We also demonstrate that net accumulation and
efflux of TCA cycle intermediates is responsive to FAO in skeletal
muscle mitochondria. Its extent, and the specific metabolites that
are exported, depend on FAO rate. Future studies utilizing
targeted metabolomics are required to further characterize and
quantify TCA cycle cataplerosis during oxidation of different
substrates, at different rates, in skeletal muscle, as well as to better
understand anaplerotic mechanisms.
Supporting Information
Figure S1 14C-Palmitate oxidation rates for the three palmitate
conditions tested. Complete (14CO2) and incomplete (14C-ASP)
oxidation were determined. Data were re-plotted from Seifert et
al., 2008.
Found at: doi:10.1371/journal.pone.0009834.s001 (0.13 MB PPT)
Figure S2 Palmitate oxidation rate is associated with unique
shifts in TCA cycle intermediates, fatty acids, and amino acids.
Presented is a simplified overview of the findings presented in
Figures 5–7 and S1, and, for clarity, does not include every
pathway and fate of each metabolite. Only the detected TCAi are
shown. Low palmitate oxidation rate is associated with the efflux
of citrate (panel A). Since matrix levels of citrate do not decrease,
anaplerotic replenishment of citrate is occurring. Exogenously
provided malate is one likely anaplerotic substrate. Amino acids
may be another source. Also effluxed at the low oxidation rate are
C12 and C14 fatty acids; these may be derived from b-oxidation
reactions, through cleavage of acyl-CoA units by a thioesterase, or
may be derived from membrane-bound pools. In contrast (panel
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citrate without export, whereas a-ketoglutarate efflux is promi-
nent. The amino acid pool associated with the matrix fraction
diminishes, likely reflecting the anaplerotic replenishment of TCA
cycle intermediates. Note that amino acids that are not classically
found in the mitochondrial matrix were detected in the matrix
fraction; this may reflect pathways that are intimately associated
with mitochondria. TCA: tricarboxylic acid; ASP: acid soluble
product.
Found at: doi:10.1371/journal.pone.0009834.s002 (0.50 MB PPT)
Table S1 Bioenergetic status of murine skeletal muscle mito-
chondria oxidizing palmitate: Supplementary Table and accom-
panying Results and Discussion.
Found at: doi:10.1371/journal.pone.0009834.s003 (0.05 MB
DOC)
Table S2 Complete listing of metabolites detected in each
condition according to criteria described in Methods.
Found at: doi:10.1371/journal.pone.0009834.s004 (0.16 MB
XLS)
Methods S1 Methods for the determination of absolute amounts
of metabolites.
Found at: doi:10.1371/journal.pone.0009834.s005 (0.03 MB
DOC)
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